Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.
COVID-19
PREVENTIVE MEDICINE
Public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
This study focused on Bulgarian patient cohorts harbouring a single documented chronic comorbidity-cardiovascular pathology, an oncological disease or a chronic pulmonary diseases (CPD) comparing the outcomes in fully vaccinated and non-vaccinated populations classified by sex and age groups in ambulatory, hospital and intensive care unit (ICU) settings at the national level. Retrospective analysis SETTINGS, PARTICIPANTS AND OUTCOME MEASURES: In total, 1 126 946 patients with confirmed COVID-19, on a national level, were retrospectively analysed between March 2020 and April 2022, using data from the Ministry of Health's United Information Portal, launched in March 2020. Of all the confirmed 247 441 hospitalised cases of COVID-19, 67 723 (27.3%) had documented cardiovascular disease (CVD), 2140 (0.9%) had confirmed solid malignancy (regardless of stage) and 3243 (1.3%) had established CPD as their only chronic pathology. The number of cumulative deaths in each subgroup was 10 165 (in-hospital=5812 and ICU=4353); 4.0% vaccinated (410/10 165, p<0.001), 344 (in-hospital=196 and ICU=148), 4.9% vaccinated (17/344, p<0.001), 494 (in-hospital=287 and ICU=207) and 5.2% vaccinated (26/494, p<0.001), respectively. Statistical significance (p<0.001) was obtained in favour of reduced ambulatory, hospitalisation and both in-hospital and ICU-related mortality in the vaccinated cohorts, and BNT162b2 was the most effective at preventing mortality in all age groups. This retrospective analysis shows that patients vaccinated against COVID-19 demonstrated trends of reduced hospitalisations and premature mortality in patients with CVD, solid malignancy or CPD as a single comorbidity.
Identifiants
pubmed: 37532478
pii: bmjopen-2022-068431
doi: 10.1136/bmjopen-2022-068431
pmc: PMC10401219
doi:
Substances chimiques
BNT162 Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e068431Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nat Rev Nephrol. 2022 Jul;18(7):409-410
pubmed: 35414006
Nat Med. 2022 Jun;28(6):1105-1106
pubmed: 35534571
BMJ Glob Health. 2022 May;7(5):
pubmed: 35618305
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Nat Rev Immunol. 2022 Jun;22(6):333-334
pubmed: 35440758
BMC Public Health. 2022 Jan 9;22(1):54
pubmed: 35000578
Vaccine. 2021 Jul 5;39(30):4029-4031
pubmed: 34120766
BMJ. 2021 Aug 20;374:n2015
pubmed: 34417194
BMJ. 2022 Jun 15;377:o1431
pubmed: 35705219
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
JAMA Oncol. 2022 Jun 1;8(6):1-2
pubmed: 35452089
Sci Rep. 2021 Nov 23;11(1):22777
pubmed: 34815503
MMWR Morb Mortal Wkly Rep. 2022 Jan 07;71(1):19-25
pubmed: 34990440
Lancet Infect Dis. 2022 Jul;22(7):1002-1010
pubmed: 35405090
Lancet. 2022 Apr 16;399(10334):1489-1512
pubmed: 35120592
Health Policy. 2022 May;126(5):456-464
pubmed: 35221121
Med Ref Serv Q. 2020 Jan-Mar;39(1):67-74
pubmed: 32069199